Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.
Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH; TRAFFIC Investigators. Lederman RJ, et al. Among authors: annex bh. Lancet. 2002 Jun 15;359(9323):2053-8. doi: 10.1016/s0140-6736(02)08937-7. Lancet. 2002. PMID: 12086757 Clinical Trial.
Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial.
Rajagopalan S, Mohler E 3rd, Lederman RJ, Saucedo J, Mendelsohn FO, Olin J, Blebea J, Goldman C, Trachtenberg JD, Pressler M, Rasmussen H, Annex BH, Hirsch AT; Regional Angiogenesis With Vascular Endothelial Growth Factor trial. Rajagopalan S, et al. Among authors: annex bh. Am Heart J. 2003 Jun;145(6):1114-8. doi: 10.1016/S0002-8703(03)00102-9. Am Heart J. 2003. PMID: 12796772 Clinical Trial.
Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH. Rajagopalan S, et al. Among authors: annex bh. Circulation. 2003 Oct 21;108(16):1933-8. doi: 10.1161/01.CIR.0000093398.16124.29. Epub 2003 Sep 22. Circulation. 2003. PMID: 14504183 Clinical Trial.
Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease.
Rajagopalan S, Olin JW, Young S, Erikson M, Grossman PM, Mendelsohn FO, Regensteiner JG, Hiatt WR, Annex BH. Rajagopalan S, et al. Among authors: annex bh. Hum Gene Ther. 2004 Jun;15(6):619-24. doi: 10.1089/104303404323142060. Hum Gene Ther. 2004. PMID: 15212720 Free article. Clinical Trial.
Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.
Powell RJ, Goodney P, Mendelsohn FO, Moen EK, Annex BH; HGF-0205 Trial Investigators. Powell RJ, et al. Among authors: annex bh. J Vasc Surg. 2010 Dec;52(6):1525-30. doi: 10.1016/j.jvs.2010.07.044. J Vasc Surg. 2010. PMID: 21146749 Free PMC article. Clinical Trial.
Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training.
Jones WS, Duscha BD, Robbins JL, Duggan NN, Regensteiner JG, Kraus WE, Hiatt WR, Dokun AO, Annex BH. Jones WS, et al. Among authors: annex bh. Vasc Med. 2012 Apr;17(2):94-100. doi: 10.1177/1358863X11436334. Epub 2012 Mar 8. Vasc Med. 2012. PMID: 22402934 Free PMC article. Clinical Trial.
201 results